
Pharma R&D, what's hot in 2011 and beyond?
With closure and even divest of discovery sites in US and
At a time of “Pharma R&D: Thinking big, acting small”, Asia Pharma R&D Leaders (APRDL) is staged back again to present another great event for pharma R&D industry leaders all over the world with special interests in pharma R&D opportunities in Asian emerging markets and with views to optimize their R&D capabilities in the region. Asia Pharma R&D Leaders 2011 (APRDL 2011) will provide you with the best practice you need to know for wining emerging market in
Why you can not miss
Develop new business models in 2011 and beyond for pharma R&D geared toward cost efficiency and ROI improvement
Navigate Asia market trends for heavily invested therapeutics areas: Oncology, CNS and Metabolic Diseases
Lay foundations for effective partnership with top China CRO, biotech and academia
Touch with latest advancement in Stem Cell, Antibody, and Peptide discoveries
Learn from best practice in managing research, balancing costs, risk and profits
Explore mass in-licensing opportunities in Asia emerging markets in response to new world R&D order
Meet 1 on 1 with your end buyers who plan to outsource R&D to Asia from Europe or US
Build right contacts in big pharma for your early stage discoveries and identify how deals can be done in Asia
Identify late stage opportunities in Asia to gain competitiveness when facing patent cliff in 2011
